Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Dompe` Farmaceutici S P A is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single pending action represents the entirety of the company's active prosecution efforts at this time. The presence of 1 pending office action suggests a focused or emerging portfolio rather than a high-volume filing approach, indicating a strategic selection of pharmaceutical innovations for patent protection.
The prosecution is handled by 1 distinct examiner located in 1 distinct art unit. Having only 1 distinct examiner and 1 distinct art unit indicates that the current legal challenges and reviews are confined to a very specific niche within the patent office's organizational structure. This concentration allows for a direct and singular focus on the requirements of one specific art unit, which can be beneficial for maintaining consistency in the application of examination standards.
CHERNYSHEV, OLGA N is the busiest examiner for this portfolio, with 1 busiest examiner pending action. Because the total pending office actions also number 1, CHERNYSHEV, OLGA N is responsible for the company's entire pending workload. This match between the busiest examiner's load and the total pending actions highlights the centralized nature of the current examination process, where the outcome depends on the review of this single individual.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.4% |
| DEBERRY, REGINA M | 1 | 50.1% | +30.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19423385 | INTRANASAL ADMINISTRATION OF NGF FOR THE PREVENTION OR TREATMENT OF RETINOPATHIES AND OPTIC NERVE DISORDERS | DEBERRY, REGINA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19562175 | NERVE GROWTH FACTOR AND METHODS OF USE THEREOF FOR NEURODEVELOPMENTAL DISABILITIES ASSOCIATED WITH NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY | CHERNYSHEV, OLGA N | — |
| 19423385 | INTRANASAL ADMINISTRATION OF NGF FOR THE PREVENTION OR TREATMENT OF RETINOPATHIES AND OPTIC NERVE DISORDERS | DEBERRY, REGINA M | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19562175 | NERVE GROWTH FACTOR AND METHODS OF USE THEREOF FOR NEURODEVELOPMENTAL DISABILITIES ASSOCIATED WITH NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY | CHERNYSHEV, OLGA N | 1675 | DP | Final Rejection | — | Pending | Mar 10, 2026 |
| 19423385 | INTRANASAL ADMINISTRATION OF NGF FOR THE PREVENTION OR TREATMENT OF RETINOPATHIES AND OPTIC NERVE DISORDERS | DEBERRY, REGINA M | 1647 | §102§103§112 | Non-Final OA | — | Pending | Dec 17, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial